White Paper

Genome-Editing: The Value of CRISPR’s Intellectual Property

The CRISPR IP landscape can often seem like a labyrinth. ARK aims to summarize the key CRISPR stakeholders and collaborations, including: i) licenses from patent holders, ii) sub-licenses from surrogates to collaborators, iii) areas of CRISPR research, and iv) exclusive vs. non-exclusive licenses.

ARK believes the IP battle will result in cross-licensing agreements and the global proliferation of CRISPR technology. While it may be years until we have a resolution, the benefits of CRISPR are already tangible. To download the full white paper, please fill out the form.

You also may be interested in our white paper:

CRISPR Genome-Editing Market Opportunity and Key Players.

You are leaving ark-invest.com
By clicking below you acknowledge that you are navigating away from ark-invest.com and will be connected to ark-funds.com ARK Investment Management LLC manages both web domains. Please take note of ARK’s privacy policy, terms of use, and disclosures that may vary between sites.